Thursday, 15th November Clinical Oncology Society of Australia Annual Scientific Meeting 2018

• Advanced cancer patient perspectives on consenting to molecular tumour profiling: A qualitative study - Nicole Bartley
• A bioinformatics approach to biomarker validation using publically available RNAseq data from immunotherapy trials - Wee Loong Chin
• Psychotropic combined with Chemotherapeutics Drug Interaction Tool: An Essential Time-Saving Resource for Clinicians - Graham Rivers
• Complementary and alternative medicine use by patients receiving curative-intent chemotherapy - Peter J Smith
• Avelumab treatment of Australian patients with metastatic Merkel cell carcinoma (mMCC): experience from an expanded access program (EAP) - Tom van Hagen
• Potential role for a novel body composition analysis technique in patients with malignant pleural mesothelioma - Emily Jeffery

• Upskilling the primary care workforce in cancer survivorship - Jon Emery
• An Optimal care pathway for Aboriginal and Torres Strait Islander people – closing the gap on culturally safe cancer care - Jenny Post
• Improving outcomes for Aboriginal and Torres Strait Islander people with cancer through an Optimal Care Pathway - Jennifer Chynoweth
• Measuring Financial Toxicity in Australian Cancer Patients – validation of the COmprehensive Score for financial Toxicity (COST) - Kimberley Durber
• Assessing the impact of outreach Oncology clinics in remote New South Wales. - Sashie Howpage
• Repetitive blood testing in medical oncology ward inpatients – a retrospective six week audit of incidence, clinical yield and cost in a large Sydney tertiary referral hospital - Abhijit Pal
• Estimating the cost benefit of radiotherapy for 5-year local control and overall survival - Jesmin Shafiq
• Can we prospectively assess the value for money of oncology clinical trials? - Haitham Tuffaha

Speaker: Prof Dorothy Keefe and A/Prof Michael Franco
Description: To discuss the latest antiemetic guideline recommendations and treatment options in chemotherapy induced nausea and vomiting (CINV). This will include the use of NK-1 receptor antagonists or “triple therapy” in patients receiving carboplatin or oxaliplatin – containing chemotherapy agents, emerging evidence in dexamethasone-sparing antiemetic regimens, and data on the NEPA combination as well as olanzapine in CINV control and prevention. This session with explore the data to support the use of TARGIN® tablets in the treatment of chronic cancer pain in daily doses up to 160/80 mg, examine the importance of the ongoing assessment of hepatic function and outline how to manage safe opioid rotation from TARGIN® tablets in light of deteriorating liver function. examine the importance of the ongoing assessment of hepatic function and outline how to manage safe opioid rotation from TARGIN® tablets in light of deteriorating liver function. 

• Supporting the patient with personality vulnerability during cancer care - Jane Turner
• Case presentation: A multi-disciplinary systemic approach to caring for the complex patient with serious mental illness during chemotherapy (including tips for safely managing psychotropics and steroid therapy) - Lisa Miller
• Panel Discussion: Managing complex delirium in cancer patients - Lisa Miller

• Impact of financial costs of cancer on patients – the Australian experience - Christine L Paul
• Patient Out-of-Pocket Expenses - Sanchia Aranda
• Measuring Financial Toxicity in Australian Cancer Patients – validation of the COmprehensive Score for financial Toxicity (COST) - Kimberley Durber
• Medicines Access Programs to cancer medicines in Australia and New Zealand: An exploratory study - Piyush Grover

Panel Discussion at end

• The WHO (2017) Classification: What's Changed? - Chris Hemmings
• Evolving treatment modalities and current clinical trials in NETs - Nick Pavlakis
• New discoveries in tumour biology that might matter in the clinic - Ben Lawrence

Chair: Linda Mileshkin

9:00am Linda Mileshkin: Introduction

• Clinical impact of the CUPGuide and Comprehensive Cancer Panel in the SUPER national prospective study: experience of the first 2 years - Tharani Sivakumaran
• New horizons in translational research of cancer of unknown primary - Richard W Tothill
• Poor understanding of the diagnosis predicts psychological morbidity in Cancer of Unknown Primary patients. - Penelope Schofield
• Experiencing Cancer of Unknown Primary as a Carer: perspectives from the SUPER study consumer - Cindy Bryant
• Development of the Optimal Care Pathway for Cancer of Unknown Primary   - Linda Mileshkin

• Mice, Meso and Exercise - Scott A Fisher
• Exercise for patients with mesothelioma - Carolyn J McIntyre
• Challenges in physical activity for colorectal cancer survivors - Janette Vardy
• Implementing Exercise in Cancer Care - Prue Cormie

• The politics of cancer - Tim Hammond